The WACC of Fuso Pharmaceutical Industries Ltd (4538.T) is 5.2%.
| Range | Selected | |
| Cost of equity | 6.10% - 8.70% | 7.40% |
| Tax rate | 24.70% - 26.70% | 25.70% |
| Cost of debt | 4.00% - 4.50% | 4.25% |
| WACC | 4.5% - 5.9% | 5.2% |
| Category | Low | High |
| Long-term bond rate | 1.4% | 1.9% |
| Equity market risk premium | 6.1% | 7.1% |
| Adjusted beta | 0.77 | 0.88 |
| Additional risk adjustments | 0.0% | 0.5% |
| Cost of equity | 6.10% | 8.70% |
| Tax rate | 24.70% | 26.70% |
| Debt/Equity ratio | 1.05 | 1.05 |
| Cost of debt | 4.00% | 4.50% |
| After-tax WACC | 4.5% | 5.9% |
| Selected WACC | 5.2% | |
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for 4538.T:
cost_of_equity (7.40%) = risk_free_rate (1.65%) + equity_risk_premium (6.60%) * adjusted_beta (0.77) + risk_adjustments (0.25%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.